The clinical and pathologic implications of plasmacytic infiltrates in percutaneous renal allograft biopsies.
Plasmacytic infiltrates in renal allograft biopsies are uncommon and morphologically distinctive lesions that may represent variants of acute rejection. This study sought significant clinical and pathologic determinants that might have influenced development of these lesions and assessed their prognostic significance. Renal allograft biopsies (n = 19), from 19 patients, with tubulointerstitial inflammatory infiltrates containing abundant plasma cells, composing 32 +/- 8% of the infiltrating mononuclear cells, were classified using Banff '97 criteria. Clonality of the infiltrates was determined by immunoperoxidase staining for kappa and lambda light chains and polymerase chain reaction for immunoglobulin heavy-chain gene rearrangements, using V(H) gene framework 3 and JH consensus primers. In situ hybridization for Epstein-Barr virus encoded RNA (EBER) was performed in 17 cases. The clinical features, histology, and outcome of these cases were compared with kidney allograft biopsies (n = 17) matched for time posttransplantation and type of rejection by Banff '97 criteria, with few plasma cells (7 +/- 5%). Sixteen of 19 biopsies (84%) with plasmacytic infiltrates had EBER-negative (in 14 cases tested) polyclonal plasma cell infiltrates that were classifiable as acute rejection (types 1A [4], 1B [10], and 2A [2]). These biopsies were obtained between 10 and 112 months posttransplantation. Graft loss from acute and/or chronic rejection was 50% at 1 year and 63% at 3 years, and the median time to graft failure was 4.5 months after biopsy. There was no significant difference in overall survival or time to graft failure compared with the controls. Three of 19 biopsies (16%) had EBER-negative polyclonal plasmacytic hyperplasia, mixed monoclonal and polyclonal polymorphous B cell hyperplasia, and monoclonal plasmacytoma-like posttransplantation lymphoproliferative disease (PTLD) and were obtained at 17 months, 12 weeks, and 7 years after transplantation, respectively. Graft nephrectomies were performed at 1, 19, and 5 months after biopsy, respectively. Plasmacytic infiltrates in renal allografts comprise a spectrum of lesions from acute rejection to PTLD, with a generally poor prognosis for long-term graft survival.
Meehan
S M
SM
Department of Pathology, University of Chicago, Chicago, IL 60637, USA.
Domer
P
P
Josephson
M
M
Donoghue
M
M
Sadhu
A
A
Ho
L T
LT
Aronson
A J
AJ
Thistlethwaite
J R
JR
Haas
M
M
D000328:Adult; D001706:Biopsy; D002452:Cell Count; D004247:DNA / Q000032:analysis; D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000473:pathology; D005260:Female; D015321:Gene Rearrangement; D005803:Genes, Immunoglobulin; D006084:Graft Rejection / Q000473:pathology* / Q000628:therapy / Q000821:virology; D004854:Herpesvirus 4, Human / Q000302:isolation & purification / Q000472:pathogenicity; D006801:Humans; D007124:Immunoenzyme Techniques; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D017403:In Situ Hybridization; D016030:Kidney Transplantation / Q000473:pathology*; D008232:Lymphoproliferative Disorders / Q000473:pathology* / Q000821:virology; D008297:Male; D008875:Middle Aged; D009395:Nephritis, Interstitial / Q000473:pathology / Q000821:virology; D010950:Plasma Cells / Q000473:pathology*; D011183:Postoperative Complications; D012367:RNA, Viral / Q000032:analysis; D014184:Transplantation, Homologous
C106732:Epstein-Barr virus encoded RNA 2; D007166:Immunosuppressive Agents; D012367:RNA, Viral; D004247:DNA